Anti-IL6 therapy (tocilizumab) showed a positive clinical response in a small group of patients in AS, CD, and RA, suggesting its application in other IMIDs like psoriasis and UC (65–67). This evidence concerns the gene IL6 and rheumatoid arthritis.